July 29, 2021 -- Sartorius Stedim Biotech has acquired cell culture company Xell, which is headquartered in Bielefeld, Germany.
Xell develops, produces, and sells media and feed supplements for cell cultures for use in viral vector manufacturing of gene therapies and vaccines. The company also offers analytical services for characterizing, screening, and quantifying media components, as well as media composition optimization. The privately owned company employs approximately 35 people and is expected to generate revenue of approximately 5 million euros ($5.9 million U.S.) in 2021. Xell also recently completed a facility expansion at its headquarters.
Sartorius purchased Xell for an agreed-upon price of 50 million euros ($59.4 million) in addition to two earn-out components that are contingent on the achievement of defined revenue targets in 2022 and 2025.
The acquisition expands Sartorius' offerings in specialized media for viral vectors and media analytics, it said.